Bracco Diagnostics Inc. and Lantheus Medical Imaging Enter into Agreement to Co-Promote Bracco’s CardioGen-82® (Rubidium Rb 82 Generator)

PRINCETON, N.J. & N. BILLERICA, Mass.--(BUSINESS WIRE)--Bracco Diagnostics Inc., the US-based subsidiary of Bracco Imaging SpA and part of the Bracco Group, and Lantheus Medical Imaging, Inc., both worldwide leaders in diagnostic imaging, announced today that the companies have entered into an agreement for Lantheus to co-promote Bracco’s CardioGen-82® (Rubidium Rb 82 Generator), a myocardial perfusion Positron Emission Tomography (PET) imaging agent. CardioGen-82 is the only generator-based PET perfusion agent approved by the U.S. Food and Drug Administration (FDA) and reimbursed for the evaluation of coronary artery disease (CAD).

Back to news